tiprankstipranks
Blurbs

Analysts Offer Insights on Healthcare Companies: Leap Therapeutics (LPTX) and Atara Biotherapeutics (ATRA)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Leap Therapeutics (LPTXResearch Report) and Atara Biotherapeutics (ATRAResearch Report) with bullish sentiments.

Leap Therapeutics (LPTX)

In a report issued on January 23, Mara Goldstein from Mizuho Securities maintained a Buy rating on Leap Therapeutics, with a price target of $6.00. The company’s shares closed last Thursday at $1.82.

According to TipRanks.com, Goldstein is a 4-star analyst with an average return of 5.8% and a 37.6% success rate. Goldstein covers the Healthcare sector, focusing on stocks such as Adaptimmune Therapeutics, Iovance Biotherapeutics, and Neoleukin Therapeutics.

Currently, the analyst consensus on Leap Therapeutics is a Strong Buy with an average price target of $5.67, representing a 220.3% upside. In a report issued on January 24, Robert W. Baird also maintained a Buy rating on the stock with a $5.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Atara Biotherapeutics (ATRA)

Mizuho Securities analyst Salim Syed maintained a Buy rating on Atara Biotherapeutics on January 24 and set a price target of $41.00. The company’s shares closed last Thursday at $9.55, close to its 52-week low of $8.24.

According to TipRanks.com, Syed has 0 stars on 0-5 stars ranking scale with an average return of -14.0% and a 36.9% success rate. Syed covers the Healthcare sector, focusing on stocks such as Coherus Biosciences, Unity Biotechnology, and Wave Life Sciences.

Atara Biotherapeutics has an analyst consensus of Strong Buy, with a price target consensus of $36.25, implying a 296.2% upside from current levels. In a report issued on March 1, Canaccord Genuity also maintained a Buy rating on the stock with a $67.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on LPTX:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More